Jan 10 2019 In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q […]Continue Reading ...
With funding provided by the German Research Foundation (DFG) for the Collaborative Research Center/Transregio 128, researchers at the Medical Center of Johannes Gutenberg University Mainz (JGU) identified an innovative and promising therapeutic option to treat multiple sclerosis. They discovered that the protein prohibitin occurs in high concentrations on the surface of certain T cells in […]Continue Reading ...
Home News FDA Alerts Gilenya (fingolimod): Drug Safety Communication – Severe Worsening of Multiple Sclerosis After Stopping the Medicine November 20, 2018 Audience: Patient, Health Professional, Neurology, Pharmacy ISSUE: FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started […]Continue Reading ...
A recent article by a team of international experts on multiple sclerosis (MS) underscores the importance of expanding the knowledge base about the hippocampus in order to better understand the genesis of cognitive deficits and develop new treatment strategies. The article, “The hippocampus in multiple sclerosis”, was published in The Lancet Neurology 2018;17:918-926. (doi: 10.1016/S1474-4422(18)30309-0) […]Continue Reading ...
siponimod Treatment for Multiple Sclerosis Novartis Announces FDA and EMA Filing Acceptance of Siponimod for Secondary Progressive Multiple Sclerosis (SPMS) Basel, October 08, 2018 – Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s New Drug Application (NDA) and Marketing Authorization Application (MAA) […]Continue Reading ...
FRIDAY, Sept. 28, 2018 — Living with a potentially disabling condition like multiple sclerosis (MS) can be difficult, but new research suggests patients get better at dealing with it over time. “There’s an aging paradox in healthy adults. We expect people who are older to be more depressed and anxious because of aging processes [such […]Continue Reading ...
Sep 24 2018 The link between smoking and multiple sclerosis (MS) is “clearer than ever”, the MS Society has announced. Not only are people who smoke more likely to develop MS, smoking can also speed up how fast people with MS become disabled. Ahead of October’s annual ‘Stoptober’ campaign, an independent research review by the […]Continue Reading ...
A recent brief report by MS researchers provides preliminary evidence that older individuals with multiple sclerosis (MS) report lower levels of depression and higher quality of life than their younger counterparts. These findings are consistent with the trend toward improvement in well-being with age in the general population. The article, “Subjective well-being differs with age […]Continue Reading ...
In an editorial published in CNS Spectrums, Jay Avasarala, MD, PhD, takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS). Noting that the disease course of MS in African American (AA) patients is more aggressive, he urged researchers to make […]Continue Reading ...
John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada. The award funds a collaborative study with the University of Alabama at Birmingham (UAB) titled “Effects of Walking Exercise Training on […]Continue Reading ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. This online content initiative was created following extensive research from 13,500 […]Continue Reading ...
Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s New Drug Application (NDA) and Marketing Authorization Application (MAA) respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS) in adults. This phase of multiple sclerosis (MS) can […]Continue Reading ...
Home News Professional Lower Levels of Depression, Higher QOL for Older MS Patients WEDNESDAY, Sept. 26, 2018 — Older individuals with multiple sclerosis (MS) report less severe depressive symptoms and better physical quality of life (QOL), compared to younger patients, according to a brief report recently published in Rehabilitation Psychology. Noting that increased age is […]Continue Reading ...
Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya® (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis (RRMS). If approved, Gilenya® is expected to be the first oral […]Continue Reading ...
Source: Getty Images In a phase 2 clinical trial, an investigational anti-inflammatory drug called ibudilast was found to be superior to placebo in slowing the progression of brain atrophy in patients with progressive multiple sclerosis. The study, conducted at 28 sites around the country, including Columbia University Irving Medical Center, was published last month in […]Continue Reading ...
- Breast cancers more likely to metastasize in young women within 10 years of giving birth
- Blood vessels can now be created perfectly in a petri dish
- Young-Onset Type 2 Diabetes Tied to Increased Hospitalization Risk
- For-profit nursing schools associated with lower performance on nurse licensure test
- Considering the culture of consent in medicine
- Researchers identify comprehensive guidelines for managing severe atopic dermatitis
- Analyzing proteins in blister fluid may classify burn severity more accurately
- Study finds higher suicide rates among youth who were Medicaid enrollees
- Opioid drugs often overprescribed to children for pain relief, say CHOP surgeons
- New biodegradable wound dressing material accelerates healing
- Life in Space May Take Toll on Spinal Muscles
- Bulldogs’ screw tails linked to human genetic disease
- Immunotherapy target identified for pediatric cancers
- Financial stress may increase heart disease risk in African Americans
- Scientists solve another piece of Ebola virus puzzle
- New project finds how endocrine disruptors interfere with thyroid functions
- Research finds decline in ketone body utilization when coronary circulation is reduced
- Let’s map our DNA and save billions each year in health costs
- AI demonstrates potential to identify irregular heart rhythms as well as humans
- Study shows link between air pollution and increased risk of sleep apnea